TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage

Area of Science:

• Hepatology
• Virology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infection presents a significant global health challenge, increasing the risk of liver cirrhosis and cancer.
• Current treatment strategies for HCV require effective direct-acting antivirals for combination therapy to achieve high cure rates and shorter treatment durations.

Purpose of the Study:

• To evaluate the in vitro inhibitory activity, mechanism of action, binding kinetics, and resistance profile of TMC647055, a novel non-nucleoside inhibitor targeting the HCV NS5B RNA-dependent RNA polymerase.
• To assess the potential of TMC647055 in combination therapy with an HCV NS3/4A protease inhibitor for suppressing HCV RNA replication.

Main Methods:

• In vitro assessment of TMC647055's antiviral activity against HCV.
• Characterization of its mode of action, binding kinetics, and resistance patterns.
• In vitro combination studies with an HCV NS3/4A protease inhibitor.

Main Results:

• TMC647055 demonstrated potent in vitro inhibition of the HCV NS5B RNA-dependent RNA polymerase.
• Combination studies showed synergistic suppression of HCV RNA replication when TMC647055 was used with an NS3/4A protease inhibitor.
• The compound exhibited a promising in vitro biochemical, kinetic, and virological profile.

Conclusions:

• TMC647055 is a potent non-nucleoside inhibitor of HCV replication via NS5B polymerase inhibition.
• Combination therapy involving TMC647055 and an NS3/4A protease inhibitor holds potential for treating chronic HCV infection.
• The promising in vitro profile of TMC647055 warrants its ongoing clinical evaluation.